AlloVir appoints Shawn Tomasello to board; co-founder John Wilson to retire

Kalaris Therapeutics, Inc.

Shawn Tomasello appointed to Board of Directors effective March 29, 2022, serving as Class III director until 2023 annual meeting.
John Wilson, co-founder and former executive director, will retire and not stand for re-election at 2022 annual meeting.
Ms. Tomasello brings over 35 years of life sciences experience, with specific expertise in cell and gene therapy commercialization.
Board determined Ms. Tomasello is independent under Nasdaq listing standards; she will receive standard non-employee director compensation.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shawn Tomasello

Director

KLRS · Kalaris Therapeutics, Inc.

Effective: 2022-03-29
Filed: March 31, 2022, 7:59 PM ET

On March 29, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of AlloVir, Inc. (“AlloVir”), the Board appointed Shawn Tomasello to the Board, effectively immediately.

Departed

John Wilson

Director

KLRS · Kalaris Therapeutics, Inc.

Filed: March 31, 2022, 7:59 PM ET

on March 29, 2022, John Wilson notified the Board that he will be retiring from the Board and will not stand for re-election at AlloVir’s 2022 annual meeting of shareholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shawn Tomasello was appointed as director at Kalaris Therapeutics, Inc..

Action: appointed

Exact text from the filing

On March 29, 2022, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of AlloVir, Inc. (“AlloVir”), the Board appointed Shawn Tomasello to the Board, effectively immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Wilson departed as director at Kalaris Therapeutics, Inc..

Action: retiring

Exact text from the filing

on March 29, 2022, John Wilson notified the Board that he will be retiring from the Board and will not stand for re-election at AlloVir’s 2022 annual meeting of shareholders.

View on SEC.gov

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-090667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.